Uses of rose pigment compounds

US10105313B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10105313-B2
Application numberUS-201515311612-A
CountryUS
Kind codeB2
Filing dateMay 19, 2015
Priority dateMay 19, 2014
Publication dateOct 23, 2018
Grant dateOct 23, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An object of the present invention is to provide hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, and collagen synthesis promoters that contain as an active component one or more pigment compounds that are obtained as extracted from plants of the family Rosaceae, as well as agents for cutaneous application, skin cosmetics, and quasi-drugs that contain such pigment compounds. The present invention provides hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, collagen synthesis promoters, agents for cutaneous application, skin cosmetics, and quasi-drugs that contain one or more compounds in a class of rosacyanins or one or more compounds in a class of rosadelphins as an active component.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of inhibiting hyaluronidase, comprising administering an effective amount of, as an active component, one or more compounds selected from the group consisting of a compound in a class of rosacyanins as represented by the following general formula (I): [where R 1 and R 2 , taken together, form —O—; or alternatively, R 1 is the following group (a): {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms} or the following group (b): and R 2 is OH]; and a compound in a class of rosadelphins as represented by the following general formula (II): {where R 1 is the following formula (a): {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms} and R 2 is OH; or R 1 and R 2 , taken together, form —O—; or R 1 is the following group (b): and R 2 is —OH}, to a subject in need thereof. 2. The method according to claim 1 , wherein the compound in the class of rosacyanins is one or more compounds selected from the group consisting of rosacyanin A1 represented by the following formula: {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms}, rosacyanin A2 represented by the following formula: and rosacyanin B represented by the following formula: 3. The method according to claim 1 , wherein the compound in the class of rosacyanins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosacyanins. 4. The method according to claim 3 , wherein the plant of the family Rosaceae that contains the compound in the class of rosacyanins is one or more plants of the family Rosaceae as selected from the group consisting of Madame Violet, Purple Rain, Lavande, Manhattan Blue, Chantilly Lace, Blue Moon, Tasogare, Charles de Gaulle, Violet Dolly, Blue Ribbon, Aozora, Lady X, Blue Bajou, and Sterling Silver. 5. The method according to claim 1 , wherein the compound in the class of rosadelphins is one or more compounds selected from the group consisting of rosadelphin A1 represented by the following formula: {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms}, rosadelphin A2 represented by the following formula: and rosadelphin B represented by the following formula: 6. The method according to claim 1 , wherein the compound in the class of rosadelphins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosadelphins. 7. The method according to claim 6 , wherein the plant of the family Rosaceae that contains the compound in the class of rosadelphins is a plant of the family Rosaceae that contains the flavonoid 3′, 5′-hydroxylase gene. 8. The method according to claim 1 , wherein administration of said one or more compounds suppresses matrix metalloproteinase 1 (MMP-1) production. 9. The method according to claim 1 , wherein administration of said one or more compounds promotes collagen synthesis. 10. The method according to claim 1 , wherein administration of said one or more compounds is cutaneous administration. 11. A method of inhibiting collagenase, comprising administering an effective amount of, as an active component, one or more compounds selected from the group consisting of a compound in a class of rosacyanins as represented by the following general formula (I): [where R 1 and R 2 , taken together, form —O—; or alternatively, R 1 is the following group (a): {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms} or the following group (b): and R 2 is —OH]; and a compound in a class of rosadelphins as represented by the following general formula (II): {where R 1 is the following formula (a): {provided that in group (a), the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms} and R 2 is —OH; or R 1 and R 2 , taken together, form —O—; or R 1 is the following group (b): and R 2 is —OH}, to a subject in need thereof. 12. The method according to claim 11 , wherein the compound in the class of rosacyanins is one or more compounds selected from the group consisting of rosacyanin A1 represented by the following formula: {provided that in this group, the coordination (wavy line) to the hydroxyl group at position 1 of glucose indicates tautomerism of α- and β-forms}, rosacyanin A2 represented by the following formula: and rosacyanin B represented by the following formula: 13. The method according to claim 11 , wherein the compound in the class of rosacyanins is administered as an extract of a plant of the family Rosaceae that contains the compound in the class of rosacyanins. 14. The method according to claim 13 , wherein the plant of the family Rosaceae that contains the compound in the class of rosacyanins is one or more plants of the family Rosaceae as selected from the group consisting of Madame Violet, Purple Rain, Lavande, Manhattan Blue, Chantilly Lace, Blue Moon,

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Drugs for dermatological disorders · CPC title

  • A61K8/19Primary

    containing inorganic ingredients · CPC title

  • Magnoliopsida [dicotyledons] · CPC title

  • Glycosides, e.g. rutin · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10105313B2 cover?
An object of the present invention is to provide hyaluronidase inhibitors, collagenase inhibitors, elastase inhibitors, MMP-1 production suppressors, and collagen synthesis promoters that contain as an active component one or more pigment compounds that are obtained as extracted from plants of the family Rosaceae, as well as agents for cutaneous application, skin cosmetics, and quasi-drugs that…
Who is the assignee on this patent?
Suntory Holdings Ltd
What technology area does this patent fall under?
Primary CPC classification A61K8/19. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).